Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Mar 24 2016

Full Issue

Viewpoints: Patent Laws And High Drug Prices; Medicare's Move To Step Up Diabetes Prevention

A selection of opinions from around the country.

High prescription drug prices make most Americans' blood boil, with the same drugs costing up to six times more here than in Western Europe, where drug prices are regulated. However, one cause of high prices has received scant attention: the delays in bringing generic drugs to the market. This problem, costing consumers billions of dollars each year, should be a top priority for Dr. Robert M. Califf, who was just confirmed by the Senate as the new Commissioner of the Food and Drug Administration (FDA). (Andrew L. Yarrow, 3/23)

One of the biggest stories in science right now is the fight over the Crispr patents. Crispr is a gene editing technique that promises to allow previously unthinkable feats of bio-engineering. It was discovered in stages, like most scientific breakthroughs, by multiple teams working at various universities and research institutes around the world. The final, key advancements were made more-or-less simultaneously by two teams of researchers -- one based in California and led by Jennifer Doudna and Emmanuelle Charpentier, the other based at the Broad Institute in Massachusetts and headed by Feng Zhang. (Noah Smith, 3/23)

Current efforts to enhance rewarding value rather than volume of health care focus principally on transitioning fee-for-service Medicare payments into alternative payment models, such as accountable care organizations or bundled payment arrangements. But to promote rewarding value, we also need to focus on long-term prevention that can improve outcomes over the long run. The Center for Medicare & Medicaid Innovation, under the Centers for Medicare & Medicaid (CMS), recently announced a model test for population-based reductions in projected 10-year cardiovascular risk. But many other opportunities for prevention-focused innovative payment models remain. One important opportunity is addressing chronic conditions such as type 2 diabetes. (Sameed Ahmed M. Khatana, Ann L. Albright and Darshak M. Sanghavi, 3/23)

Senate Democrats recently ramped up their efforts to force businesses to pay managerial employees overtime. The reform is only the latest attempt by Democrats to tamper with — and ultimately ruin — our economy through wage and price controls. Both Hillary Clinton and Bernie Sanders, for instance, support a dramatic hike in the federal minimum wage, as well as Medicare overhauls that amount to government price controls on drugs. All of these proposals mistakenly assume that the federal government knows better than businesses and consumers what goods and labor are worth. (Michelle Ray, 3/23)

The Centers for Disease Control and Prevention's new guidelines for doctors on responsibly prescribing painkillers such as Oxycontin and Vicodin bring important additional attention to the opioid crisis gripping our nation. The CDC's reason for issuing these guidelines is clear – almost 29,000 people fatally overdosed on prescription opiates or heroin in 2014 – and addiction continues to be a growing problem in communities across the United States. (Chuck Ingoglia and Becky Vaughn, 3/23)

The crisis that led officials in Ithaca, N.Y., to consider opening a supervised-injection center for heroin users, part of what the United States Centers for Disease Control and Prevention has called a national epidemic of overdose deaths, is sadly familiar to us here. Overdose deaths and H.I.V. infection among injection drug users were so high nearly 20 years ago that Vancouver declared a public health emergency. With open drug use and needles discarded in the streets of downtown Vancouver, we responded in 2003 by opening North America’s first supervised-injection center for heroin and other injection drugs. (Patricia Daly, 3/23)

You think of yourself as proactive and prepared. You’ve thought through a smart retirement plan. Your car maintenance is up to date. Even your dog’s shots are up to date. But have you had your Medicare annual wellness visit? Probably not. According to Medicare, fewer than 20% of those who qualify for this free benefit take advantage of it. If you care about your health and long-term well-being, it’s a benefit you can’t afford to pass up. (Molly Mettler, 3/23)

The newly dead have stories to tell and lessons to teach. But we aren’t listening. Autopsy, once a mainstay of medicine, is now often an afterthought. (Mary Fowkes, 3/23)

While public health officials in the western hemisphere are trying to figure out how to stop the mosquito-borne Zika virus, few seem to have noticed that, even if eliminated in a year or two, the Zika virus could have profound long-term demographic effects in affected countries. (Robert Book, 3/23)

It’s a case of bad news and lousy publicity adding up to good, remedial legislation. On Wednesday, Gov. Rick Scott signed into law one bill that creates a needle-exchange program to battle and, it is hoped, slow the spread of HIV through intravenous drug use. The governor also put his signature on legislation that requires state crime labs to test rape kits within 120 days of receiving them. These two bills alone speak highly of lawmakers’ bipartisan effort to tackle head-on two unsustainable scourges. And we commend Gov. Scott for following through, acknowledging the challenges that the laws will now confront. (3/23)

The festival, which was co-founded by Robert De Niro in 2002, has placed a film purporting to defend Wakefield and accusing the Centers for Disease Control and Prevention of a cover-up on its program this spring. The film is called "Vaxxed: From Cover-Up to Conspiracy." Its director: Andrew Wakefield. (Michael Hiltzik, 3/23)

The abundant deficiencies of Gov. Rick Snyder's administration are laid bare in a scathing report issued Wednesday by the task force the governor himself appointed to postmortem the Flint water crisis. The appointment of this task force was the governor's response, in the days after he finally acknowledged that the water in Flint was not safe to drink, to critics demanding accountability from an administration that for too long seemed unmoved by the events unfolding in Flint. (3/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ